The Company leases office and research and development facilities and equipment under various non-cancellable operating lease agreements. In January 2010, the Company entered into a lease for office and laboratory space in Malvern, Pennsylvania (the “Malvern Lease”). The Malvern Lease commenced in March 2010 and was amended to extend its term to September 30, 2023. This lease contains escalating rent payments. In December 2018, the Company entered into a lease for office space in San Diego, California, which expires in October 2022.

The Company’s future minimum commitments under its non-cancelable operating leases were as follows (in thousands):

Year Ending December 31,
2019	$	342
2020		368
2021		373
2022		360
2023		204
Thereafter		—
Total	$	1,647

The Company recognizes rent expense for the facility operating leases on a straight-line basis. The Company accounts for the difference between the minimum lease payments and the straight-line amount as deferred rent. Rent expense was $0.4 million for the years ended December 31, 2018 and 2017.

The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company’s business, operating results, financial condition or cash flows.

The Company has entered into a Master Services Agreement (“Supply Agreement”) with BioVectra Inc., (“BioVectra”). BioVectra will manufacture and supply cGMP-grade quantities of the Company’s PB2452 proprietary drug product (“Product”) for the Company’s potential PB2452 Phase 3 clinical trial as well as any work required to support the marketing authorization filing. A Commercial Supply Agreement is being put in place for the Product, if it is approved by the FDA.

BioVectra is responsible for the facility, including performing all work related to the procurement, design, project management, installation, assembly, commissioning and validation of the facility and all equipment, and for financing all costs associated with building out the facility. The Company will be responsible for the purchase of certain equipment and raw materials for the production process.